No headlines found.
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
Globe Newswire (Fri, 29-Mar 9:00 AM ET)
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
Globe Newswire (Thu, 7-Mar 4:01 PM ET)
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
Globe Newswire (Tue, 27-Feb 8:00 AM ET)
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.
Adagene - Ads Each Representing 1.25 trades on the NASDAQ stock market under the symbol ADAG.
As of May 10, 2024, ADAG stock price climbed to $2.23 with 46,522 million shares trading.
ADAG has a beta of 0.18, meaning it tends to be less sensitive to market movements. ADAG has a correlation of 0.00 to the broad based SPY ETF.
ADAG has a market cap of $97.66 million. This is considered a Micro Cap stock.
In the last 3 years, ADAG stock traded as high as $20.98 and as low as $.90.
ADAG has outperformed the market in the last year with a return of +59.3%, while the SPY ETF gained +27.8%. However, in the most recent history, ADAG shares have underperformed the stock market with its stock returning -39.4% in the last 3 month period and -6.7% for the last 2 week period, while SPY has returned +4.2% and +2.5%, respectively.
ADAG support price is $1.96 and resistance is $2.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADAG stock will trade within this expected range on the day.